Free Trial
NYSE:RFL

Rafael Q2 2025 Earnings Report

Rafael logo
$1.46 +0.12 (+8.52%)
Closing price 05/7/2025 03:58 PM Eastern
Extended Trading
$1.46 -0.01 (-0.68%)
As of 07:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rafael EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Rafael Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rafael Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, March 13, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Rafael's Q3 2025 earnings is scheduled for Friday, June 13, 2025, with a conference call scheduled on Tuesday, June 10, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Rafael Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Rafael Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rafael? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rafael and other key companies, straight to your email.

About Rafael

Rafael (NYSE:RFL) primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

View Rafael Profile

More Earnings Resources from MarketBeat